$LQDA

Boyle Dana sold $644K of LQDA

Boyle Dana (Chief Accounting Officer) sold 9,002 shares of Liquidia Corp (LQDA) at an average of $71.51 ($71.39–$71.52, $0.64M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Boyle Dana
Published Jul 14, 2026, 11:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 12:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The only new information is the disclosed sale details and that it was executed under a pre-arranged 10b5-1 plan, which generally reduces interpretive value.

02

Market read

Traders may note the insider sale for sentiment monitoring, but it is unlikely to drive a fundamental repricing by itself.

03

What to watch

The article does not disclose any concurrent corporate event, earnings timing, or changes in guidance; the sale size is moderate relative to typical institutional flows.

Relevance 4/10Novelty 3/10Timing: After-hours/filing update on July 14 for a July 13 insider sale.

Background

The article is an SEC Form 4 insider transaction disclosure for Liquidia Corp, reported by CFO Boyle Dana.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia Corp insider Form 4 shows CFO Boyle Dana sold 9,002 shares in open-market trades totaling about $643.7K on July 13.

Expected impact

Likely minimal impact on the stock price; any effect is typically short-lived and outweighed by broader catalysts.

Evidence & confidence

The filing is a disclosed open-market sale by an accounting officer, explicitly under a pre-arranged 10b5-1 plan, and provides no new company-specific operational or financial information.

Market effects

No clear sector read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with periods of reduced confidence, so traders may watch for follow-on insider activity or changes in trading patterns.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider transaction disclosure.

  • Boyle Dana

    Chief Accounting Officer who sold shares in open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAHighAI 8/10

Why is Liquidia stock cratering today?

Liquidia Corporation's stock fell 48.3% to $36.55 after a court ruled it infringed two claims of United Therapeutics' patent, impacting its YUTREPIA drug. The company plans to remove a key indication and may face further restrictions. United Therapeutics' stock rose. The broader market gained slightly.